Celldex Therapeutics, Inc. (CLDX) Q2 2013 Earnings Results

Celldex Therapeutics Misses on EPS — Stock Down 4.73%

Celldex Therapeutics reported a loss that was slightly worse than expected, which contributed to a 4.73% drop in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. Overall, the results reflect ongoing challenges in the business environment.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.24	N/A	-7.62%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about current market conditions impacting performance. They did not provide a clear outlook for future revenue.

Management did not provide specific revenue guidance for the upcoming quarters.

The company acknowledged challenges in achieving profitability.

Celldex Therapeutics Misses on EPS — Stock Down 4.73%

Key numbers

Management commentary

Celldex Therapeutics, Inc.

More earnings this week

Celldex Therapeutics Misses on EPS — Stock Down 4.73%

Key numbers

Management commentary